We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Atara Biotherapeutics, Inc.는 암 및 자가면역 질환 환자를 위한 혁신적인 치료제를 국내외에서 개발하고 있습니다. 주요 제품으로는 EBV 관련 이식 후 림프증식성 질환 및 기타 EBV 유발 질환 치료를 위해 임상 3상 시험 중인 T세포 면역치료제 프로그램인 Tab-cel (tabelecleucel)이 있습니다. 또한 B세포 악성 종양 및 자가면역 질환 치료를 위한 CD19 표적 동종유래 CAR T 치료제인 ATA3219도 개발하고 있습니다. 회사는 Memorial Sloan Kettering Cancer Center 및 Council of the Queensland Institute of Medical Research와 연구 협력 계약을 체결했습니다. Atara Biotherapeutics, Inc.는 2012년에 설립되었으며, 본사는 캘리포니아주 사우전드 오크스에 있습니다.